KVP Capital Advisors, LP holds a focused book of 35 stocks worth $136.2M as of Q2 2026 (disclosed Aug 13, 2026, a ~44-day 13F lag). This quarter they opened Erasca Inc and trimmed Axsome Therapeutics Inc. Their largest long position is Praxis Precision Medicines I at 11% of the equity book. Cloning the disclosed picks since 2026 would be +46% (+105.4%/yr). That is a simulation of the disclosed long book, not audited returns.
Growth of $10,000 cloning KVP Capital Advisors, LP's disclosed long 13F book, rebalanced on each filing date (so it reflects each quarter's actual reporting lag, ~44 days for the latest filing, with no look-ahead), total-return basis (dividends reinvested), derived from end-of-day prices. “Their reported book” values the same picks from quarter-end, before they were public. S&P 500 is SPY total return over the same window. Excludes shorts, cash, options and non-13F holdings. Not investment advice.
Top-heavy: focused book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
100% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Other tracked managers holding the same core names as KVP Capital Advisors, LP
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| BlackRock, Inc. | 40 / 35 | $14.6B |
| UBS Group AG | 40 / 35 | $2.0B |
| MORGAN STANLEY | 40 / 35 | $2.0B |
| NORTHERN TRUST CORP | 40 / 35 | $1.2B |
| VANGUARD FIDUCIARY TRUST CO | 40 / 35 | $1.0B |
| VANGUARD CAPITAL MANAGEMENT LLC | 39 / 35 | $7.3B |
| JPMORGAN CHASE & CO | 39 / 35 | $4.6B |
| GOLDMAN SACHS GROUP INC | 39 / 35 | $1.7B |
Ranked by how many of KVP Capital Advisors, LP's top 35 disclosed names each fund also holds: a cross-fund conviction signal from the latest 13F of every tracked manager.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Praxis Precision Medicines I COM NEW | $14.4M | 42.9K | 10.5% | —Held | |
| 2 | Whitehawk Therapeutics Inc COM | $9.9M | 2.17M | 7.3% | —Held | |
| 3 | Erasca Inc COM | $8.3M | 455.0K | 6.1% | ▲New New position | |
| 4 | Trevi Therapeutics Inc COM | $7.7M | 414.0K | 5.7% | —Held | |
| 5 | Sutro Biopharma Inc COM SHS | $7.5M | 226.6K | 5.5% | ▲New New position | |
| 6 | Tango Therapeutics Inc COM | $7.2M | 230.3K | 5.3% | ▲New New position | |
| 7 | MBX Biosciences Inc COM | $6.7M | 121.5K | 4.9% | —Held | |
| 8 | Protagonist Therapeutics Inc COM | $6.5M | 53.0K | 4.8% | —Held | |
| 9 | Edgewise Therapeutics Inc COM | $5.4M | 133.0K | 4.0% | —Held | |
| 10 | Tandem Diabetes Care Inc COM NEW | $4.5M | 301.0K | 3.3% | ▲New New position | |
| 11 | Disc Medicine Inc COM | $4.3M | 58.3K | 3.1% | —Held | |
| 12 | Savara Inc COM | $3.7M | 605.3K | 2.7% | —Held | |
| 13 | Arrivent Biopharma Inc COM | $3.5M | 102.0K | 2.6% | ▲New New position | |
| 14 | Insmed Inc COM PAR $.01 | $3.0M | 28.5K | 2.2% | —Held | |
| 15 | Achieve Life Sciences Inc COM | $3.0M | 462.4K | 2.2% | —Held | |
| 16 | Ideaya Biosciences Inc COM | $3.0M | 79.7K | 2.2% | ▲New New position | |
| 17 | Ocular Therapeutix Inc COM | $2.9M | 300.0K | 2.2% | ▲New New position | |
| 18 | Axsome Therapeutics Inc. COM | $2.9M | 12.0K | 2.2% | ▼−67% Reduced · −24K sh | |
| 19 | Design Therapeutics Inc COM | $2.7M | 185.0K | 2.0% | ▲New New position | |
| 20 | United Therapeutics Corp Del COM | $2.6M | 4.8K | 1.9% | —Held | |
| 21 | Scholar Rock Hldg Corp COM | $2.5M | 45.0K | 1.8% | —Held | |
| 22 | Immix Biopharma Inc COM | $2.4M | 230.4K | 1.7% | —Held | |
| 23 | Viridian Therapeutics Inc COM | $2.3M | 125.0K | 1.7% | ▲New New position | |
| 24 | Mineralys Therapeutics Inc COM | $2.3M | 84.2K | 1.7% | ▲New New position | |
| 25 | Bright Minds Biosciences Inc COM NEW | $2.2M | 31.8K | 1.6% | ▲New New position | |
| 26 | Travere Therapeutics Inc COM | $2.2M | 39.0K | 1.6% | ▼−57% Reduced · −52K sh | |
| 27 | Zura Bio Ltd CLASS A ORD SHS | $2.2M | 373.1K | 1.6% | ▲New New position | |
| 28 | Artiva Biotherapeutics Inc COM | $1.9M | 200.0K | 1.4% | ▲New New position | |
| 29 | Nektar Therapeutics COM NEW | $1.9M | 26.9K | 1.4% | —Held | |
| 30 | Compass Therapeutics Inc COM | $1.7M | 771.0K | 1.2% | ▲New New position | |
| 31 | Cabaletta Bio Inc COM | $1.6M | 505.4K | 1.2% | —Held | |
| 32 | Vera Therapeutics Inc CL A | $1.4M | 32.7K | 1.0% | —Held | |
| 33 | Evolus Inc COM | $1.0M | 150.0K | 0.8% | ▲New New position | |
| 34 | Celcuity Inc COM | $418K | 4.0K | 0.3% | —Held | |
| 35 | Vyne Therapeutics Inc COM | $326K | 500.6K | 0.2% | —Held |
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1858198/holdings"
Use Arkolith to show KVP Capital Advisors, LP's latest holdings, largest changes, and filing provenance.
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | Aug 13, 2026 | 35 | $136.2M | 13F-HR |
| Q1 2026 | Feb 18, 2026 | Feb 18, 2026 | 27 | $103.3M | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. The performance line is a simulation of the disclosed long book, not an audited return.